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Letters to the Editor:

Posterior cortical atrophy (PCA) is a neurodegenerative disorder characterized by progressive visuospatial and visuoperceptual deficits \[[@CR1]\]. The dynamics of its progression and clinical outcome are not well known. Pathological studies have shown that Alzheimer's disease (AD) is the most common underlying etiology of PCA. However, a small number of cases are also reported with other degeneration diseases \[[@CR2]\]. The exact genetic basis of PCA remains unclear, however, mutations have been reported in the prion protein gene (*PRNP*) \[[@CR3]\], presenilin 1 and 2 genes (*PSEN1* and *PSEN2*) \[[@CR4]\], microtubule-associated protein tau gene (*MAPT*) \[[@CR5]\], and progranulin gene (*GRN*) \[[@CR6]\], suggesting heterogeneity of its genetic mechanism. Here, we describe a case of a PCA patient with initial visual problems, who developed further cognitive impairments and asymmetric extrapyramidal signs that fitted with a diagnosis of corticobasal syndrome (CBS).

The patient's initial symptoms were discovered in early 2009 at the age of 52, as it was noted that he took longer time to return home alone than before. He also began to complain of blurred vision, but it did not affect his daily life. Two years later, he began to suffer from progressive spatial disorientation. He was unable to fetch objects with either arm by visual guidance. His memory also began to decline and sometimes he spoke not fluently. In 2012, he exhibited problems in writing simple words, calculating and discerning fingers. He walked more slowly and sometimes exhibited tremor and myoclonus of his upper limbs, especially his right side. In May 2013, he complained of deterioration and difficulty in tracking specific objects in his visual field. He also had difficulty in riding, dressing himself, and distinguishing coats from pants. He urinated anywhere as he could not find the bathroom, and he even occasionally defecated on himself. Structural brain magnetic resonance imaging (MRI) in a local hospital revealed cerebral atrophy, particularly in the posterior cortex (Fig. [1a, b](#Fig1){ref-type="fig"}). He was diagnosed with AD. After 6 months, he stopped donepezil treatment since his symptoms got more severe.Fig. 1The clinical materials of the case. **a**-**b** Axial sections, T1-weighted sequences of MRI 4 years after disease onset (at 56 years of age) revealed cerebral atrophy, particularly in the posterior cortex. **c**-**d** One and a half years later, the secondary MRI revealed much more extensive atrophy within the frontal and occipital-parietal lobes, and bilateral partial parietal lobe. **e**-**f** 18F-FDG-PET showed diffuse bilateral hypometabolism in the frontal, parietal, temporal, and occipital lobes, particularly in the parieto-occipital regions. **g** Bilateral fundus examinations were normal. **h** Genetic testing showed a single nucleotide polymorphism rs5848 (c.\*78C \> T), located in the 3′-UTR of *GRN*

Positive neurological system signs included reduced facial expression, increased muscle tone and bradykinesia especially on the right side and a little resting tremor on his right side. His performance in neuropsychological evaluations (Table [1](#Tab1){ref-type="table"}) suggested that he had problems in visual spatial, memory, language, and motor functions. He had no significant past medical history and no family history of dementia.Table 1Neuropsychological profile of the patientTestsPatient's score/Maximal scoreMini-mental State Examination (MMSE) scores6/30 Time and location (orientation)1/10 Immediate recall1/3 Repetition1/1 Naming2/2 Executive function1/3Montreal Cognitive assessment Scale (MoCA) ScoresUnfinished (noncooperation)Boston naming test (30 items)6/30Clock drawing test0/4Forward digit-span task4Backward digit-span task2Plane copy0Three dimensional copy0Rey complex figure test0Trail making test AUnfinishedTrail making test BUnfinishedHamilton Anxiety Scale (HAMA)-17 items25/68Hamilton Depression Scale (HAMD)-17 items24/68Activities of Daily living (ADL) scale-14 items48/64Hachinski Ischemic Scale (HIS)3/18

Secondary MRI revealed marked cortical atrophy within the frontal and occipito-parietal lobes, and partial atrophy in the bilateral parietal lobes (Fig. [1c, d](#Fig1){ref-type="fig"}). 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) showed diffuse bilateral hypometabolism in the frontal, parietal, temporal, and occipital lobes, particularly in the occipito-parietal regions (Fig. [1e, f](#Fig1){ref-type="fig"}). Ophthalmology examination found that his fundus (Fig. [1g](#Fig1){ref-type="fig"}) and intraocular pressure were normal. His visual evoked potential was nearly normal, while his visual field and visual acuity examinations were not completed because of noncooperation. A laboratory blood screening test for reversible dementia was unremarkable. Lumber puncture showed normal cerebrospinal fluid (CSF) pressure, glucose, chlorine, cell number, and protein levels. Normal total-tau, phosphorylated-tau, and amyloid-β (Aβ) 1--42 levels were also reported in CSF. No pathogenic mutations in early-onset AD-associated genes (including *APP*, *PS1*, *PS2*, *BACE1*, and *PRNP*) were found. The patient's *APOE* genotype was E3/E3. However, testing for frontotemporal lobar degeneration (FTLD) -associated gene (*GRN*, *CHMP2B*, *FUS*, *MAPT*, *PSEN1*, *TARDBP* and *VCP*) mutations revealed a T allele of rs5848, locating in the 3′-UTR of *GRN* (Fig. [1h](#Fig1){ref-type="fig"}).
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Posterior cortical atrophy is a rare clinicoradiologic neurodegenerative syndrome, and two sets of clinical diagnostic criteria for PCA have been proposed \[[@CR7], [@CR8]\]. The core features of disease onset, progress forms, and main clinical manifestations are consistent, but do not illustrate its underlying pathological, genetic, or biomarker standards.

In the initial phase of our case, the symptoms were visual problems, specifically, of disorientation and blurred vision. Over time he manifested additional symptoms including optic ataxia, oculomotor apraxia, right-left disorientation, acalculia, dressing apraxia, and agraphia, fitting into the dorsal subtype of PCA. His first cerebral MRI revealed posterior cortical atrophy, also supporting his initial clinical diagnosis. As the disease progressed, the patient developed further asymmetric extrapyramidal signs and progressive global cognitive impairment, but without vertical ophthalmoplegia or apparent hallucinations. The second MRI revealed much more extensive cerebral atrophy and FDG-PET confirmed hypometabolism of those cortical regions. Given the history, clinical findings, and supporting examinations, a diagnosis of CBS was then made \[[@CR9]\].

Besides corticobasal degeneration, CBS can also be caused by such as progressive supranuclear palsy, AD, Pick's disease, FTLD with TDP-43 inclusions, mutations in *GRN* or *MAPT*, DLB, and CJD \[[@CR10]\]. Considering current clinical criteria and various pathological etiologies for PCA and CBS, there is considerable overlap, meaning that some patients may fulfill criteria for both syndromes, or develop from one syndrome to the other \[[@CR11]\].

Special biomarkers such as the CSF tau:Aβ ratio may predict pathology in CBS patients \[[@CR12]\]. In our case, CSF analysis revealed normal tau and Aβ1-42 levels, which suggests low probability of AD pathology. In addition, genetic tests identified no reported pathogenic genetic mutations for early-onset AD, and an *APOE* E3/E3 genotype. FTLD-associated gene testing revealed a genetic variant, rs5848 (c.\*78C \> T) in the 3′-UTR of the *GRN* gene, which has been reported as a risk factor for TDP-43-positive frontotemporal dementia and other neurodegenerative diseases such as AD. The *GRN* rs5848 TT genotype is reported to improve microRNA binding efficiency to the 3′-UTR of *GRN*, leading to enhanced suppression of GRN translation and reduced GRN expression \[[@CR13]\]. Tartaglia et al. \[[@CR14]\] reported a typical patient with sporadic CBS, who was homozygous for this *GRN* variant (rs5848), and without mutations in *MAPT* or *GRN* genes. Recently, Caroppo et al., \[[@CR6]\] reported a visual/ventral variant in a PCA patient carrying a heterozygous *GRN* mutation. Whether this PCA patient would develop other symptoms that meet the diagnosis of CBS, like our case, needs longitudinal follow-up and final autopsy evidence.

This study provides evidence for CBS belonging to the *GRN* genetic variant (rs5848) clinical spectrum, and demonstrates that in rare cases, CBS may initially present with symptoms of PCA. Longitudinal follow-up is required to ascertain the most likely etiology and determine the clinical-genetic-pathological mechanism of the T allele of the rs5848 polymorphism in CBS diagnosis.
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